EMPA, when combined with standard heart failure therapy, significantly improved the ejection fraction and reduced N-terminal pro-brain natriuretic peptide (NT-proBNP) levels compared to metformin in patients with mildly reduced EF [6]. The gene discussed is NPPB; the disease is heart failure.